These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 18986716)

  • 1. The dopaminergic hypothesis of attention-deficit/hyperactivity disorder needs re-examining.
    Gonon F
    Trends Neurosci; 2009 Jan; 32(1):2-8. PubMed ID: 18986716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug policy and treatment bias due to the dopamine-deficit theory of child attention-deficit hyperactivity disorder.
    Rastmanesh R
    Atten Defic Hyperact Disord; 2010 Nov; 2(3):149-57. PubMed ID: 21432601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis.
    Swanson JM; Kinsbourne M; Nigg J; Lanphear B; Stefanatos GA; Volkow N; Taylor E; Casey BJ; Castellanos FX; Wadhwa PD
    Neuropsychol Rev; 2007 Mar; 17(1):39-59. PubMed ID: 17318414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.
    Staller JA; Faraone SV
    Expert Rev Neurother; 2007 Apr; 7(4):351-62. PubMed ID: 17425490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
    Fone KC; Nutt DJ
    Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study.
    Ludolph AG; Kassubek J; Schmeck K; Glaser C; Wunderlich A; Buck AK; Reske SN; Fegert JM; Mottaghy FM
    Neuroimage; 2008 Jul; 41(3):718-27. PubMed ID: 18424180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention deficit and hyperactivity disorder: review of genetic association studies.
    Galili-Weisstub E; Segman RH
    Isr J Psychiatry Relat Sci; 2003; 40(1):57-66. PubMed ID: 12817670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses.
    Genro JP; Kieling C; Rohde LA; Hutz MH
    Expert Rev Neurother; 2010 Apr; 10(4):587-601. PubMed ID: 20367210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).
    NIH Consens Statement; 1998 Nov 16-18; 16(2):1-37. PubMed ID: 10868163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attention deficit/hyperactivity disorder across the lifespan.
    Wilens TE; Biederman J; Spencer TJ
    Annu Rev Med; 2002; 53():113-31. PubMed ID: 11818466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulant effects in attention deficit hyperactivity disorder: theoretical and empirical issues.
    Denney CB
    J Clin Child Psychol; 2001 Mar; 30(1):98-109. PubMed ID: 11294083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy.
    Noorbala AA; Akhondzadeh S
    Arch Iran Med; 2006 Oct; 9(4):374-80. PubMed ID: 17061613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of executive function in ADHD.
    Swanson JM
    J Clin Psychiatry; 2003; 64 Suppl 14():35-9. PubMed ID: 14658934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?
    Gerlach M; Grünblatt E; Lange KW
    Atten Defic Hyperact Disord; 2013 Jun; 5(2):71-81. PubMed ID: 23605387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology.
    Bolea-Alamañac B; Nutt DJ; Adamou M; Asherson P; Bazire S; Coghill D; Heal D; Müller U; Nash J; Santosh P; Sayal K; Sonuga-Barke E; Young SJ;
    J Psychopharmacol; 2014 Mar; 28(3):179-203. PubMed ID: 24526134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.
    Bellgrove MA; Hawi Z; Kirley A; Fitzgerald M; Gill M; Robertson IH
    Neuropsychopharmacology; 2005 Dec; 30(12):2290-7. PubMed ID: 16123773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychotic disorders comorbid with attention-deficit hyperactivity disorder: an important knowledge gap.
    Levy E; Traicu A; Iyer S; Malla A; Joober R
    Can J Psychiatry; 2015 Mar; 60(3 Suppl 2):S48-52. PubMed ID: 25886680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunological and endocrinological pattern in ADHD etiopathogenesis].
    Budziszewska B; Basta-Kaim A; Kubera M; Lasoń W
    Przegl Lek; 2010; 67(11):1200-4. PubMed ID: 21442976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder.
    Schweren LJ; de Zeeuw P; Durston S
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1151-64. PubMed ID: 23165220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.